ArticleArchives of virology2026
Urine as a complementary specimen for RT-qPCR detection of Oropouche virus.
Article in Archives of virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oropouche fever is an emerging arboviral disease in South America, for which reliable molecular diagnostic specimens throughout the course of infection are essential for surveillance and clinical management. This study aimed to compare the diagnostic performance of RT-qPCR in paired urine and serum samples and to evaluate temporal trends in cycle threshold (Ct) values according to time since symptom onset. A retrospective analysis was conducted on 41 paired serum–urine samples (one pair per patient) collected within 15 days after symptom onset. RT-qPCR results were classified as detectable or undetectable, with Ct values recorded when available. Positivity rates were compared using McNemar’s test, inter-matrix agreement was assessed with Cohen’s kappa, and paired Ct values were analyzed using the Wilcoxon signed-rank test. Temporal trends were evaluated according to clinical phases defined by time since symptom onset: acute phase (0–7 days) and early convalescent phase (8–14 days), and univariable logistic regression was used to assess the effect of time on detection probability. Urine samples showed a significantly higher positivity rate (75.6%, 31/41) than serum samples (43.9%, 18/41; McNemar p = 0.037), with poor agreement between matrices (Cohen’s kappa ≈ − 0.52). While serum Ct values increased over time), indicating declining detectability, urine Ct values remained showed no significant temporal trend throughout the two clinical phases. No significant association was observed between days since symptom onset and urine detection probability within 15 days. These findings suggest that urine may serve as a complementary specimen for molecular detection of Oropouche virus, particularly when serum testing occurs later in the course of infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.